LYEL
Lyell Immunopharma·NASDAQ
--
--(--)
--
--(--)
5.13 / 10
Netural
Analyst coverage is limited but shows a split: 50% Strong Buy and 50% Neutral from two providers, with a historical weighted rating of 2.53, reflecting moderate confidence. Capital flow is strong (7.74/10), with medium-term inflows positive (Medium trend = positive) while overall, block, small, large, and extra-large trends are negative. This liquidity cushion may support the stock in the near term, yet the mixed analyst view and negative broader flows warrant vigilance.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-09
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate50.0%
What is the market sentiment for LYEL?
- LYEL holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.13/10 (Netural).
